Lipocine (NASDAQ:LPCN) Stock Crosses Above 50 Day Moving Average – Time to Sell?

Lipocine Inc. (NASDAQ:LPCN)’s stock price passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $2.30 and traded as high as $2.47. Lipocine shares last traded at $2.38, with a volume of 21,514 shares changing hands.

Analyst Upgrades and Downgrades

LPCN has been the subject of several research reports. HC Wainwright reaffirmed a “neutral” rating on shares of Lipocine in a research report on Monday, April 6th. Weiss Ratings lowered shares of Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 18th. Finally, Wall Street Zen downgraded shares of Lipocine from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Lipocine presently has a consensus rating of “Hold” and an average price target of $15.00.

Lipocine Trading Down 3.6%

The stock has a market capitalization of $19.61 million, a PE ratio of -1.27 and a beta of 0.48. The company’s 50-day moving average is $2.30 and its 200 day moving average is $5.51.

Lipocine (NASDAQ:LPCN) last released its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.03). Lipocine had a negative return on equity of 66.70% and a negative net margin of 571.18%.The company had revenue of $0.12 million for the quarter, compared to analysts’ expectations of $0.16 million. Sell-side analysts forecast that Lipocine Inc. will post -1.91 EPS for the current fiscal year.

Insider Buying and Selling at Lipocine

In other news, CEO Mahesh V. Patel bought 25,000 shares of the business’s stock in a transaction that occurred on Monday, April 6th. The shares were purchased at an average cost of $2.03 per share, with a total value of $50,750.00. Following the transaction, the chief executive officer directly owned 160,679 shares in the company, valued at approximately $326,178.37. The trade was a 18.43% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director John W. Higuchi bought 40,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 7th. The stock was purchased at an average cost of $2.03 per share, for a total transaction of $81,200.00. Following the completion of the transaction, the director owned 203,797 shares in the company, valued at $413,707.91. This trade represents a 24.42% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought 213,000 shares of company stock valued at $434,600 over the last quarter. Insiders own 6.35% of the company’s stock.

Institutional Trading of Lipocine

Several large investors have recently added to or reduced their stakes in the company. Citadel Advisors LLC acquired a new position in shares of Lipocine in the third quarter valued at about $41,000. Jane Street Group LLC acquired a new stake in shares of Lipocine during the fourth quarter worth about $85,000. Dimensional Fund Advisors LP lifted its holdings in shares of Lipocine by 57.5% during the first quarter. Dimensional Fund Advisors LP now owns 19,122 shares of the specialty pharmaceutical company’s stock worth $153,000 after purchasing an additional 6,982 shares during the period. ADAR1 Capital Management LLC purchased a new stake in Lipocine in the first quarter valued at approximately $185,000. Finally, Renaissance Technologies LLC boosted its position in Lipocine by 3.6% in the fourth quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock valued at $300,000 after buying an additional 1,300 shares during the last quarter. Hedge funds and other institutional investors own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.